Utilization of genetic testing in men with advanced prostate cancer

Autor: Jonathan A. Aguiar, Eric V. Li, Mohammad R. Siddiqui, Moataz A. Soliman, Sai K. S. R. Kumar, Edward M. Schaeffer, Mary Kate Keeter, C. Hendricks Brown, Brittany M. Szymaniak, Ashley E. Ross

Publikováno v: The Prostate. 83:516-523

Genetic evaluation of men with advanced prostate cancer is recognized as imperative both to guide treatment decisions and to trigger cascade genetic testing of family members. Here we investigate utilization patterns of genetic testing among a contem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f375ee67f300d44d8b490ca4301c3e74
https://doi.org/10.1002/pros.24480

Genetically Informed Prostate Cancer Treatment for Metastatic Disease

Autor: Yazan Numan, Alicia K. Morgans, Aisha L. Siebert, Brittany M. Szymaniak

Publikováno v: Urologic Clinics of North America. 48:365-371

Germline testing should be performed to support treatment selection for patients with metastatic prostate cancer, and should be identified in patients with high-risk localized disease. Patients with germline BRCA1/2 mutations should be educated regar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f500bfc1649e5bc6199515fecdaa3271
https://doi.org/10.1016/j.ucl.2021.03.006

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC

Autor: Daniel C. Danila, Daniel J. George, Celestia S. Higano, Charles J. Ryan, Veda N. Giri, Ana M. Molina, Zachery R. Reichert, Rana R. McKay, Julie N. Graff, Elisabeth I. Heath, Young E. Whang, Alicia K. Morgans, Emmanuel S. Antonarakis, Mary-Ellen Taplin, Akash Patnaik, Jake Vinson, Channing J. Paller, Matthew Rettig, Heather H. Cheng, Mallika Sachdev Dhawan, Tomasz M. Beer, Brittany M. Szymaniak, Maria I. Carlo, Glenn Liu, Lauren A. Facchini, Daniel P. Petrylak, Shilpa Gupta

Publikováno v: JCO oncology practice, vol 16, iss 12
JCO Oncol Pract

Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e9739fc663350096ea23710c714fb11
https://doi.org/10.1200/op.20.00431

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021

Autor: Jennifer M, Weiss, Samir, Gupta, Carol A, Burke, Lisen, Axell, Lee-May, Chen, Daniel C, Chung, Katherine M, Clayback, Susan, Dallas, Seth, Felder, Olumide, Gbolahan, Francis M, Giardiello, William, Grady, Michael J, Hall, Heather, Hampel, Rachel, Hodan, Gregory, Idos, Priyanka, Kanth, Bryson, Katona, Laura, Lamps, Xavier, Llor, Patrick M, Lynch, Arnold J, Markowitz, Sara, Pirzadeh-Miller, Niloy Jewel, Samadder, David, Shibata, Benjamin J, Swanson, Brittany M, Szymaniak, Georgia L, Wiesner, Andrew, Wolf, Matthew B, Yurgelun, Mae, Zakhour, Susan D, Darlow, Mary A, Dwyer, Mallory, Campbell

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN. 19(10)

Identifying individuals with hereditary syndromes allows for timely cancer surveillance, opportunities for risk reduction, and syndrome-specific management. Establishing criteria for hereditary cancer risk assessment allows for the identification of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::96c384fbabc6e5c37a321f2f14a185d1
https://pubmed.ncbi.nlm.nih.gov/34666312

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Autor: Robert Pilarski, Arthur L. Burnett, Lucia R. Languino, Colette Hyatt, Jacqueline Powers, Robert B. Den, Alberto Briganti, Veda N. Giri, Lorelei A. Mucci, Daniel P. Petrylak, Oliver Sartor, Amie Blanco, Daniel W. Lin, Himisha Beltran, E. David Crawford, Karen E. Knudsen, Mary-Ellen Taplin, Brian T. Helfand, Felix Y. Feng, Costas D. Lallas, E. Michael D. Scott, Wayne H. Pinover, R. Jeffrey Karnes, Scott Weissman, Evan Y. Yu, Timothy R. Rebbeck, Ashley H. Woodson, Matthew J. Schiewer, Todd M. Morgan, William B. Isaacs, Jeffrey N. Weitzel, Alanna Kulchak Rahm, Michael S. Cookson, James A. Eastham, S. Bruce Malkowicz, Neha Vapiwala, Kevin R. Loughlin, Raoul S. Concepcion, Ana Maria Lopez, Jose Moreno, Brock O'Neil, Patrick T. Gomella, Patrick Mille, Charnita Zeigler-Johnson, Howard M. Sandler, Kathleen A. Cooney, William Tester, Sarah M. Nielsen, Thomas J. Polascik, Richard C. Wender, Howard R. Soule, Ronald E. Myers, Scott E. Eggener, Marc B. Garnick, Stacy Loeb, Martin Miner, Anthony J. Costello, Gerald L. Andriole, Amanda E. Toland, David Y.T. Chen, Albert Dobi, Joseph K Izes, Mary B. Daly, Leonard G. Gomella, Mark D. Hurwitz, J. Kellogg Parsons, Matthew L. Freedman, Nathan Handley, Adam P. Dicker, Jianfeng Xu, Michael Russell Mullane, Charles J. Ryan, Edouard J. Trabulsi, Anne Calvaresi, James Ryan Mark, Thenappan Chandrasekar, Colin C. Pritchard, Saud H. AlDubayan, Curtis A. Pettaway, William Kevin Kelly, Lindsey Byrne, Peter R. Carroll, Brittany M. Szymaniak, Alicia K. Morgans, Peter A. Pinto, William L. Dahut, Mark Mann, Ganesh V. Raj, James L. Mohler, Wendy Poage, Heather H. Cheng, Grace L. Lu-Yao

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 24

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a0090e4e87cd120ef0899e6263c77c
https://escholarship.org/uc/item/3mg229rb